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Abstract
The enantioselective synthesis of FD-891 has been achieved with a longest linear sequence of 21
steps. The synthetic strategy involves the use of aldol additions of a chlorotitanium enolate of N-
acylthiazolidinthiones as the key reaction to establish 6 of the 10 stereogenic centers. A key cross-
metathesis and a late stage Julia olefination serve to assemble three key subunits.
FD-891, a 16-membered macrolide isolated from the fermentation broth of Streptomyces
graminofaciens A-8890, has been shown to have cytotoxic activity in vitro against several
tumor cell lines.1 The activity is reportedly similar to that of concanamycin A, a specific
inhibitor of vascular-type H+-ATPase.2 Recently, concanamycin A has been shown to
specifically inhibit perforin-dependent cytotoxic T lymphocyte (CTL)-mediated cytotoxicity,
but not affect Fas ligand (FasL)-dependent CTL-mediated cytotoxicity; these two cytotoxic
pathways play an essential role in the maintenance of tissue homeostasis.3 Conversely, FD-891
was found to potently prevent both perforin and FasL-dependent CTL-mediated killing
pathways, but did not inhibit vacuolar acidification.4
The relative and absolute configuration of FD-891 was elucidated after extensive spectroscopic
analysis and partial degradation.5 The structure was subsequently revised based on x-ray
analysis of partial structures.6 While substantial synthetic accomplishments have been made
on related plecomacrolides,7 to date only three reports of synthesis of fragments of FD-891
have appeared.8
Herein we report the first total synthesis of FD-891. A convergent strategy exploiting the
assembly of three subunits 2, 3, and 4 of similar complexity was anticipated for the synthesis
of FD-891 (Scheme 1). Fragments 2 and 3 were envisioned to undergo selective cross-
metathesis leading to a subsequent lactonization to give the macrocyclic core. The late-stage
installation of the C19–C25 fragment 4 would be accomplished via a Julia olefination. The
three key fragments would derive from synthons 5 and 6 accessible through the application of
the versatile aldol additions of chlorotitanium enolates of N-acylthiazolidinethiones recently
advanced in our laboratory.9
The synthesis of the C3–C12 unit 2 began with addition of known aldehyde 710 to the
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of the alcohol (Scheme 2). Reductive removal of the auxiliary directly gave aldehyde 9, which
was rapidly transformed to pivaloate 10 in three steps. Selective removal of the primary silyl
ether11 followed by Sharpless epoxidation12 gave epoxide 11 in 72% yield. Dess-Martin13
oxidation of alcohol 11, and subsequent chelate-controlled allylation of the resultant
aldehyde14 delivered the expected epoxyalcohol as single detectable diastereomer (dr >20:1).
Protection of the alcohol as its TBS ether produced the required C3–C12 unit 2.
The synthesis of fragment 3 commenced with an aldol addition between 3-butenal15 and the
enolate of thiazolidinethione 8 under conditions9a to give the non-Evans syn aldol adduct 6 in
73% yield (>15:1 dr) (Scheme 3). Protection of the alcohol delivered silyl ether 12 whereupon
reduction of the N-acylthiomide gave alcohol 13. Homologation of alcohol 13 was
accomplished by displacement of the hydroxyl with cyanide under Mitsunobu conditions16 to
provide nitrile 14. Two-stage reduction gave the corresponding diol, which underwent selective
protection to provide alcohol 15. Protection of the secondary alcohol as its acetate gave the
C13–C18 fragment 3 in 98% yield.
The synthesis of sulfone 4 began with the thioimide 12 also used in the synthesis of the C13–
C18 fragment. The aldehyde obtained by the direct reduction of thioimide 12 was subjected to
a second aldol iteration to provide the aldol adduct 16 in 87% yield. The methyl ketone 17 was
obtained by transacylation of the auxiliary to provide the corresponding Weinreb amide17
followed by protection of the alcohol and addition of methylmagnesium chloride. Chelation-
controlled18 reduction of the ketone provided 75% of the alcohol 18 along with 15% of the
C25 isomer, which could be recycled by oxidation-reduction. Methylation of the C25 hydroxyl
gave the corresponding C25 methyl ether. Acid catalyzed deprotection of the MOM and TES
groups followed by exposure of the diol to dimethoxypropane and p-TsOH provided acetonide
19. Ozonolysis with reductive work-up followed by a Mitsunobu reaction gave the desired
sulfide, which was oxidized to sulfone 4.
With the three key fragments in hand, their assembly was undertaken. A cross-metathesis19
between terminal alkenes 2 and 3 was performed with the Grubbs catalyst (Scheme 5). The
nature of the protecting group on the C15 alcohol had a profound influence on the selectivity
of the cross metathesis. The best E:Z ratio was obtained with the C15 acetate compared to other
esters or the free hydroxyl. The desired E olefin 20 was obtained in 68% yield along with 10%
of the Z-isomer.
The completion of the macrolactone required the extension at C3 to the dienoate. To this end,
reductive removal of the pivaloate preceded oxidation of the allylic alcohol with manganese
dioxide, and Horner-Wadsworth-Emmons olefination to deliver the dienoate 21. Hydrolysis
of ester 21 followed by Yamaguchi macrolactonization20 gave the desired macrocycle 22.
Selective deprotection of the primary silyl ether and oxidation of the resultant alcohol provided
aldehyde 23 in 70% yield, ready to be coupled with the C19–C26 fragment 4 via a Julia reaction.
Julia olefination21 between aldehyde 23 and sulfone 4 provided exclusively the E-olefin 24
(Scheme 5). Global deprotection by the action of H2SiF622 gave FD-891 in 90% yield. The
spectral data of synthetic FD-891 were consistent in all respects with those reported for the
natural product.1,5,6
In conclusion, we have completed the first total synthesis of the macrolide FD-891 in 21 steps
(longest linear sequence). The versatile aldol reaction of N-acylthiazolidinethione 8 was used
to create eight of the twelve stereocenters with the same enantiomer of the chiral auxiliary.
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Retrosynthetic analysis of FD-891.
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Synthesis of epoxide 2.
Conditions: (a) TiCl4, (−)-sparteine, NMP, CH2Cl2, −78 to −40 °C, 78% (dr >20:1); (b)
TBSOTf, 2,6-lutidine, CH2Cl2, −78 °C, 92%; (c) i-Bu2AlH, CH2Cl2, −78 °C, 74%; (d)
Ph3P=C(CH3)CO2Et, toluene, 80 °C, 92%; (e) i-Bu2AlH, THF, −78 °C, 98%; (f) pyridine,
PivCl, CH2Cl2, 99%; (g) NH4F, MeOH, 85%; (h) (+)-DET, (i-PrO)4Ti, t-BuOOH, molecular
sieves 4Å, CH2Cl2, −23 °C, 72% (dr 15:1); (i) Dess-Martin periodinane, NaHCO3, CH2Cl2,
97%; (j) MgBr2(Et2O), CH2=CHCH2SiMe3, CH2Cl2, −20 to −10 °C, 70% (dr >20:1); (k)
TBSCl, imid., DMAP, CH2Cl2, 99%.
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Synthesis of the C13–C18 fragment 3.
Conditions: (a) TiCl4, (−)-sparteine, 3-butenal, CH2Cl2, 0 °C, 73%; (b) TESOTf, 2,6-lutidine,
CH2Cl2, −78 °C, 96%; (c) LiBH4, Et2O, MeOH, 0°C to rt, 98%; (d) acetone cyanohydrin,
DEAD, Ph3P, toluene, 70 °C,90%; (e) i-Bu2AlH, toluene, −78 °C, 88%; (f) NaBH4, CH2Cl2,
MeOH, then HCl, 84%; (g) TBSCl, imidazole, CH2Cl2, 92%; (h) Ac2O, DMAP, Et3N,
CH2Cl2, 0 to 25 °C, 98%.
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Synthesis of sulfone 4.
Conditions: (a) i-Bu2AlH, CH2Cl2, −78 °C, 84%; (b) Thioimide 8, TiCl4, (−)-sparteine, NMP,
CH2Cl2, −78 to 0 °C, then add aldehyde, 87% (dr >20:1); (c) CH3N(OCH3)H·HCl, imidazole,
CH2Cl2, 78%; (d) MOMCl, i-Pr2NEt, DMF, 50 °C, 87%; (e) MeMgCl, Et2O, 0 °C, 97%; (f)
NaBH4, CeCl3·7(H2O), MeOH, 0 °C, 75% 18 + 15% C25 isomer which was recycled; (g) NaH,
MeI, THF, 0 °C to rt, 81%; (h) HCl (conc.), MeOH, 78%; (i) 2,2-dimethoxypropane, p-TSA,
88 %; (j) O3, CH2Cl2, MeOH, −78 °C, then NaBH4 –78 to 25 °C, 81%; (k) DIAD, 2
−mercaptobenzothiazole, PPh3, CH2Cl2, 93%; (l) H2O2 30%,(NH4)6Mo7O2 4·4H2O, EtOH,
89%.
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Conditions: (a) Cl2(Cy3P)(IMes)Ru=CHPh, CH2Cl2, 40 °C, 68% + 10% Z-isomer; (b) i-
Bu2AlH, CH2Cl2, −78 °C, 85%; (c) MnO2, CH2Cl2, 40 °C, then BuLi, Ph3P(O)C(CH3)
CO2Me, THF, 0 to 25 °C, 66% for 2 steps; (d) TMSOK, THF; (e) Cl2C6H3COCl, Et3N, THF;
then DMAP, PhCH3, 61% for 2 steps; (f) PPTS, MeOH, 90%; (g) Dess-Martin periodinane,
NaHCO3, CH2Cl2, 82%; (h) Sulfone 4, KHMDS, THF, −78 °C, then aldehyde 23, 80%; (i)
H2SiF6 20% in H2O, CH3CN, 90%.
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